XVIVO invites to its Capital Markets Day on 23 September, 2021. Dag Andersson, CEO and members of the XVIVO management team will cover company strategy, objectives and take deep dives into key projects and innovative technologies.

The event will also include sections with external guests, including Filip Rega, Professor Dr at University Hospitals Leuven and the principal investigator of XVIVOs European Heart preservation study, Brandi Zofkie, Director and Ex Vivo Lung Specialist at Lung Bioengineering and Muhammad M. Mohiuddin, Professor of Surgery and Director of the Cardiac Xenotransplantation program at University of Maryland School of Medicine. The Capital Markets Day will be moderated by financial analyst and journalist, Lars Frick.

Location: online and at Goco Health Innovation City
Date: Thursday, 23 September, 2021
Time: 13:00 – 17:00 CEST
 
Agenda
13:00 – 13:05        Introduction
13:05 – 13:20        Market & trends
13:20 – 13:35        Strategy
13:35 – 13:50        Health Economics
13:50 – 14:05        Q&A
14:05 – 14:20        Break
14:20 – 14:50        Heart
14:50 – 15:20        Abdominal
15:20 – 15:35        Q&A
15:35 – 15:50        Break
15:50 – 16:20        Lung
16:20 – 16:40        Future of transplantation
16:40 – 16:55        Q&A
16:55 – 17:00        Thank you
 
Registration
Please register to the event via this link. The Capital Markets Day will be broadcasted live online. You will receive a link to the broadcast upon your registration. Subject to availability, you are welcome to attend the Capital Markets Day in person at GoCo Health Innovation City, Kärragatan 5, 431 53 Mölndal. Please state your preferred method of attendance in your registration. Registration is open until 9 September.
 
A recording of the Capital Markets Day will be available on-demand shortly after the event, via this link.

For further information, please contact:

Kristoffer Nordström, CFO and IR, +46 73 519 21 64, e-mail: kristoffer.nordstrom@xvivogroup.com
Anne Lycke, Executive Assistant, +46 735 192 146, e-mail: anne.lycke@xvivogroup.com

About Us

Founded in 1998, XVIVO is the only medical technology company dedicated to extending the life of all major organs - so transplant teams around the world can save more lives. Our solutions allow leading clinicians and researchers to push the boundaries of transplantation medicine. XVIVO is headquartered in Gothenburg, Sweden, and has offices and research sites on two continents. The company is listed on Nasdaq and has the ticker symbol XVIVO. More information can be found on the website www.xvivogroup.com.

Attachments

XVIVO Capital Markets Day 2021